Gene Therapy for Heart Failure: Impact on Mitochondrial Dysfunction.

Area of Science:

• Cardiovascular Biology
• Mitochondrial Medicine
• Gene Therapy

Background:

• Mitochondria are crucial for cardiac function, and their dysfunction is a hallmark of heart failure (HF).
• HF involves a shift from fatty acid oxidation to glycolysis, reducing bioenergetic reserves.
• Oxidative stress and impaired mitochondrial dynamics contribute to HF progression.

Purpose of the Study:

• To review the pathophysiological mechanisms of mitochondrial dysfunction in HF.
• To explore gene therapy as a strategy to improve cardiomyocyte function.
• To highlight the potential of adeno-associated virus (AAV) vectors for cardiac gene delivery.

Main Methods:

• Review of current literature on mitochondrial dysfunction in HF.
• Analysis of gene therapy approaches targeting cardiomyocytes.
• Evaluation of AAV vector characteristics for cardiac gene delivery.

Main Results:

• Mitochondrial dysfunction, characterized by oxidative stress and altered biodynamics, significantly impacts HF.
• Gene therapy presents a viable method to address mitochondrial deficits in cardiomyocytes.
• AAV vectors show promise for efficient gene delivery to cardiac cells.

Conclusions:

• Targeting mitochondrial dysfunction via gene therapy is a potential therapeutic avenue for HF.
• AAV-mediated gene delivery offers a promising strategy to restore cardiac mitochondrial function.
• Further research into AAV vector optimization for cardiac applications is warranted.